Aim Our aim was to describe prevalence, nature, and level of severity of potential statin drug-drug interactions in a university hospital. Methods In a cross-sectional study, statin drug-drug interactions were screened from medical record of 10,506 in-patients treated stored in the clinical data warehouse BeHOP.^We screened drug-drug interactions using Theriaque and Micromedex drug databases. Results A total of 22.5% of patients were exposed to at least one statin drug-drug interaction. Given their lipophilicity and CYP3A4 metabolic pathway, atorvastatin and simvastatin presented a higher prevalence of drug-drug interactions while fluvastatin presented the lowest prevalence. Up to 1% of the patients was exposed to a contraindicated drug-drug interaction, the most frequent drug-drug interaction involving influx-transporter (i.e., OATP1B1) interactions between simvastatin or rosuvastatin with cyclosporin. The second most frequent contraindicated drug-drug interaction involved CYP3A4 interaction between atorvastatin or simvastatin with either posaconazole or erythromycin. Furthermore, our analysis showed some discrepancies between Theriaque and Micromedex in the prevalence and the nature of drug-drug interactions. Conclusions Different drug-drug interaction profiles were observed between statins with a higher prevalence of CYP3A4-based interactions for lipophilic statins. Analyzing the three most frequent DDIs, the more significant DDIs (level 1: contraindication) were reported for transporter-based DDI involving OATP1B1 influx transporter. These points are of concern to improve prescriptions of statins.
Introduction
Statins are widely prescribed across the world and have proven benefits in reducing the rate cardiovascular disease. During 2011-2012, the National Health and Nutrition Examination Survey (USA) informed that more than one-quarter (27.9%) of adults aged 40 and over reported using a prescription cholesterol-lowering medication in the past 30 days. Among US adults treated by cholesterol-lowering medication, 93% used statins with simvastatin as the most prescribed statins [1] . In France, atorvastatin was the most prescribed statin at the same period [2] . Statins have an acceptable side effect profile with mild musculoskeletal problems, such as myalgia associated with muscle problems in approximately 10 to 25% of patients treated in clinical practice [3] . The incidence of rhabdomyolysis, life-threatening adverse drug reaction, was estimated to be 3.4 per 100,000 patients per year in cohort studies. It has been reported that this incidence was different among the statin used. The frequency of rhabdomyolysis was higher (4.2 per 100,000 patients per year) with lovastatin, simvastatin, or atorvastatin that are metabolized by CYP3A4, than with pravastatin or fluvastatin which are not substrate of CYP3A4. Sixty percent of the cases of rhabdomyolysis reported in patients taking statins that are substrate of CYP3A4 [4] . This suggests that avoiding drug-drug interactions that affect some statins such as atorvastatin and simvastatin is of clinical interest to reduce potential drug-drug interaction (DDI)-related adverse drug reactions.
Statins have rather similar pharmacodynamic and toxicologic properties, while they differ on their pharmacokinetic properties as a result of differences in physico-chemical properties, and hence in their interactions with biological environment. These differences should be carefully considered to understand the different nature of drug interactions within statins occurring at the level of drug metabolism and/or at the level of membrane transporters (influx and efflux). Given that patients taking statins are polymedicamented [5] , avoiding DDIs and subsequent potential adverse drug reactions is of concern to optimize patient management. In a recent systematic review, the prevalence of DDIs with statins has been variable ranging from 0.2 to 33% depending on the interacting combinations studied, on the source (out-or in-patient records or primary care databases) and on the drug interaction database used [6] . The prevalence of clinically relevant DDIs ranged from 1.5 to 4%. However, this difference in prevalence was not unlikely given that most of the studies either searched DDIs with pre-defined interaction pairs or focused only on CYP3A4 inhibitors or have used different DDI screening program. The only study analyzing all potential DDIs of statins found a prevalence of 8.6% in ambulatory setting using Micromedex with a higher frequency for atorvastatin and simvastatin compared to fluvastatin and pravastatin [7] .
To better understand the origin (CYP450-or transporterbased DDI) and the DDI pattern of statins, we determined the prevalence, nature, and level of severity of potential DDIs of statins from electronic health records stored in our clinical data warehouse. DDIs were screened using Theriaque, and Micromedex was used for comparative analysis.
Materials and methods

Clinical data warehouse
Drug prescriptions and documented administrations to hospitalized patients were collected using the clinical data warehouse (CDW, formerly called eHOP [8] ) of the University Hospital of Rennes. The ethics committee of our institution approved the study with a waiver of patient consent authorization since the design of the retrospective cross-sectional study was non-interventional. We included in our study all patients treated with statins during their hospital stay in our institution whether statin prescription was initiated before hospitalization or during the hospital stay. The screening of potential interactions was performed on an 18-month period (January 2015 to June 2016). The overall prevalence (%) of DDIs was defined by the ratio of patients treated by statin exposed to at least one potential DDI to the total number of patients. Each DDI was counted only once per patient even though the patient was re-hospitalized and whatever the duration of the hospital stay (i.e., number of administration). The authors take responsibility for the data analysis integrity.
Drug databases
Referenced DDIs were identified using Theriaque that is a drug database (DDB) commonly used by health professionals in France [9] . For the purpose of comparative analysis, Micromedex was used as the most referenced database internationally [10] .
DDI screening program of Theriaque (version: 2016-08-24) [9] is mainly based on Thesaurus, but supplementary DDI can be integrated based on their internal literature review process. Thesaurus (version: 2016-08-12) [11] is a list of DDIs published by the Drug Interaction Working Group of the French National Agency of Medicine and Health Products safety.
Using Theriaque DDB, we identified automatically statin DDIs directly from the DDB interaction search engine comprised in the DDB interface. Using Micromedex, information on DDIs was manually extracted. Indeed, information related to clinical management of DDIs were extracted from DRUG-REAX® System available in the interaction detail of DDIs [10] .
Mapping of DDBs' grading systems
Differences in terminologies, and in the grading systems used to classify DDIs, have been observed between DDBs. However, the common point was the information dealing with the clinical management of DDIs. Hence, in order to compare the different DDBs, we defined a mapping of DDB's grading systems.
To identify DDIs, French DDBs use a grading system based on the clinical management with four levels of severity:
-Contraindication (i.e., Contre-indication): combination with serious or unpredictable risk, existence of possible alternatives. -To take into account (i.e., A prendre en compte): no specific recommendation, no specific clinical management.
We selected the first three levels of the French grading system as reference to align information from Micromedex. We decided to consider DDIs of levels of severity 1, 2, and 3 ( Fig. 1 ) since DDI assigned with these levels of severity imply a clinical decision and consequently a warning to physicians. Indeed, level «to take into account» (i.e., level 4) characterizes a DDI of minor clinical significance and was not considered in our analysis.
Micromedex uses a grading system based on a level of risk whose different levels of severity are as follows: contraindicated, major, moderate, minor, and unknown. Micromedex adds to their description of DDIs, clinical management information in an unstructured format (i.e., full-text). Consequently, we extracted information related to DDI clinical management documented in Micromedex and performed a mapping on the French grading system. The clinical management recommendations were analyzed by a pharmacist who assigned a grade for every statin DDI. The mapping between Micromedex and Theriaque (as for all French DDBs) grading system is described in Fig. 1 .
Identification of statin DDIs
We searched DDIs with statins from both pharmacokinetic or pharmacodynamic origin. These DDIs were potential DDIs since we did not analyze in this study if the interactions actually altered the activity of the drugs involved. The analysis included all prescriptions with documented administrations from all hospitalized patients during the study period. We identified potential DDIs of statins with drugs administered on the same calendar-day. To identify and collect information on potential DDIs, we selected two DDBs Theriaque and Micromedex from where we collect referenced statin DDIs. For each DDB, a list of DDIs for each statin has been generated, classified according to different level of severity, and stored in two datasets. These datasets were subsequently transferred in OrientDB database management system (a graph-oriented model database using the Spark clustercomputing framework) in order to perform multithreaded tasks. The automatic DDI identification was then performed using a customized Java-algorithm from patient's drug administrations stored in our clinical data warehouse and OrientDB database that contained the referenced DDIs. Since Theriaque was integrated in our data warehouse, the match between brand name (used for drug administration) and the corresponding International Nonproprietary Names (used for referenced statin DDIs in DDBs) was performed automatically.
Similarity assessment of DDBs
We compared similarity between the whole statin DDIs reported in Theriaque and Micromedex according to two criteria. First, we compared the presence or absence of statin DDIs between the two DDBs (i.e., global agreement). Second, using our custom grading system level ( Fig. 1) , we compared the agreement between severity levels described in the two DDBs (i.e., severity agreement).
We used Jaccard similarity coefficient to assess global agreement. Basically, the Jaccard coefficient is based on a distance measure for binary criteria such as presence or absence of a given DDI between two DDBs [12] . For global agreement, it can be considered as the percentage of similarity between DDBs based on the number of DDIs shared by two DDBs.
To measure severity agreement, we computed Kendall's tau coefficient, which is a correlation coefficient used to measure ordinal associations [13] . Severity agreement can be interpreted as the measure of relationship between DDIs ranking between DDBs. All analyses were performed on R software version 3.2.5 (2016-04-14).
Pharmacokinetics and physico-chemical properties of statins
We searched information on physico-chemical and pharmacokinetic properties of statins in the scientific literature through PubMed with the following Mesh (Medical Subject Heading) terms: statins, pharmacokinetics, DDIs, CYP450, transporters, lipophilicity and through PharmGKB, UCSF-FDA transportal and Drugbank databases.
Results
Detection of statin DDI
The study population included 10,506 hospitalized patients whose median length stay was about 7 days. The median age of included patients was 72 years ranging from 19 to 98 years. In this population, 69.1% of patients were treated by atorvastatin, 24.1% by pravastatin, 13.1% by fluvastatin, 11.3% by rosuvastatin, and 11.0% by simvastatin.
Within our study population, 22.5% of patients were identified with at least one statin potential DDI according to Theriaque (Table 1) . A more detailed analysis of DDI's prevalence by level of severity is shown in Table 2 . According to Theriaque, potential DDI's prevalence on level of severity 1 (contraindicated), severity 2 (should be avoided), and level 3 (precaution of use) were 0.2, 1.3, and 21.5%, respectively.
Prevalence of specific DDIs
The identification of the nature of statin DDIs performed for each level of severity is illustrated in Fig. 2a-c . The prevalence of DDI classified for each statin by level of severity and by DDB is summarized in Fig. 3 .
Considering all DDBs and levels of severity, we observed more DDIs for simvastatin and atorvastatin while fluvastatin was the statin with the lowest prevalence (Fig. 3) . Considering level of severity 1, rosuvastatin presented the highest prevalence of DDIs according to Theriaque, while it was simvastatin according to Micromedex.
Level 1
The most frequent DDI at the level of severity 1 using Theriaque DDB was an OATP1B1-based DDI between rosuvastatin and cyclosporin. The second and third most frequent DDIs were CYP3A4-based DDIs involving atorvastatin-itraconazole and simvastatin-erythromycin, respectively (Fig. 2a) .
It should be noticed that the most frequent DDI identified using Micromedex (i.e., between simvastatin-cyclosporin) was still a transporter-based DDI that was not considered as a contraindicated DDI by Theriaque (Fig. 2a) .
Level 2
According to Theriaque, the most frequent DDI at the level of severity 2 was a dual CYP3A4/OATP1B1-based DDI involving atorvastatin and rifampicin (Fig. 2b see supplementary materials) .
The second and third most frequent DDI according to Theriaque were atorvastatin-daptmoycin and pravastatinfenofibrate. These DDIs were of pharmacodynamic origin and presented an additive risk of myopathy.
On the opposite, according to Micromedex, the most frequent DDI identified was atorvastatin-domperidone, a CYP3A4-based DDI. The second most frequent DDI was atorvastatin-digoxin, an OATP1B1-based DDI. At last, the third most frequent DDI was atorvastatin-diltiazem. Difference in the prevalence as well as in the drug-pairing involved in the DDIs were again more evident between the two DDBs at level 2 of severity.
Level 3
On the level of severity 3, atorvastatin-fluindione was considered as the most frequent DDI with 500 patients involved (Fig. 2c, see supplementary materials) .
However, no relevant mechanism is described for this DDI. According to Micromedex, the most frequent DDI were CP3A4/OATP1B1-based DDI involving the following pairs: atorvastatin-clopidrogrel, atorvastatine-amiodarone, and simvastatin-amlodipine. These DDIs were not assessed by Theriaque at the same level of severity.
Similarity assessment of DDBs
Differences were evidenced between Theriaque and Micromedex in the prevalence of potential DDIs. While slight differences were observed for level 1 and level 3, Micromedex displayed a 5-fold higher prevalence for level 2 DDIs (Table 2) .
We extracted 217 statin DDIs referenced in Micromedex and 131 referenced in Theriaque. Global comparison between these DDBs led to a Jaccard's coefficient value of 0.40 that represents the ratio of DDIs shared by both Micromedex and Theriaque.
Severity agreement between DDBs measured by Kendall's tau coefficient was estimated to be 0.5 suggesting a moderate relationship between DDI ranking between Theriaque and Micromedex DDBs. This could be interpreted as 50% of DDIs in Theriaque and Micromedex DDBs shared the same level of severity. Fig. 2 Most frequent drug-drug interactions assessed with level of severity according to databases. The number in brackets (n) refers to the number of patients exposed to the particular DDI. The total number of patients involved was 10,506. a-c Level of severity 1 (contraindicated), 2 (generally avoided), and 3 (precaution for use), respectively
Pharmacokinetics and physico-chemical properties of statins
Data in the literature [15] [16] [17] [18] [19] [20] clearly showed difference in physico-chemical properties between statins with a decrease in lipophilicity in the following rank-order: Simvastatin > Atorvastatin > Lovastatin > Fluvastatin > Pravastatin > Rosuvastatin (Table 3 , see supplementary materials). Lipophilicity as a factor governing the intensity and mechanism of passage through cell membranes as well as the interaction with biological systems (plasma proteins, drug-metabolizing enzymes, and drug transporters) is of interest when considering DDIs (Table 3 and Fig. 4 , see supplementary materials).
Discussion
Statin DDIs
Lipophilicity is known to impact the pharmacokinetic pathway of statins either through differences in metabolism and/or 
handling by membrane transporters (Table 3 and Fig. 4, see  supplementary materials) . Hence, the nature and frequency of pharmacokinetic DDIs may potentially differ between statins.
Interactions with the most lipophilic statins (simvastatin, atorvastatin, and lovastatin) that are CYP3A4 substrates are to be considered as a result of their frequency since there are a significant number of CYP3A4 inhibitors used clinically [15] . This is clearly shown in our study where simvastatin, atorvastatin, and pravastatin clearly displayed the higher frequency of potential DDIs reaching on a whole 30.6, 20.4, and 17.8%, respectively, according to Theriaque (Fig. 3) . The lowest frequency observed with pravastatin results from the fact that this drug is metabolized by CYP3A4 but with a small extent compared to the two other statins (Fig. 3) .
It could be anticipated that lovastatin (not studied in our study because not available in France) which is a highly lipophilic statin mainly metabolized by CYP3A4 could have the same DDI profile given [14] .
Fluvastatin, a CYP2C9 substrate statin, and to a lesser extent rosuvastatin (a hydrophilic statin) had lower frequency of DDIs (Fig. 3) . Pitavastatin (not studied in our study because not yet available in France) that has physico-chemical and metabolic properties close to that of fluvastatin (Table 3) might have a low DDI profile.
The frequency of level 1 severity interactions (i.e., contraindication) was around 0.25 per 1000 hospitalizations in our study. It is noteworthy that the most frequent contraindications involved influx-transporter interactions. Indeed, OATP1B1-based drug interactions with rosuvastatin and cyclosporin as precipitant drug was ranked as level 1 severity (Fig. 2a) . Such potential DDI with rosuvastatin was not so frequent, reaching around 1% of DDI.
If CYP3A4-based DDI are quite well known, as well as the main precipitant drugs, transporter-based interactions deserve to be more considered by health professionals, especially DDI involving influx transporters at the hepatocyte level (Fig. 4 , see in supplementary materials). The higher representation of transporter-based DDI may also reflect that physicians are less aware of these DDIs compared to those mediated via CYP3A4.
Since OATP1B1-mediated hepatic uptake can be a ratelimiting step in hepatic clearance of statins, significant DDI can occur because extensive inhibition of these transporters can be achieved in clinical setting, especially via inhibition of OATP1B1, and to a lesser extent of via inhibition of OATP1B3 [16] . Indeed, above 5-fold increase in AUC (FDA threshold to be considered as clinically significant DDI) has been observed when cyclosporine has been co-administered with some statins whatever their lipophilicity [17] . These interactions involving membrane transporters are of the order of magnitude of those observed with inhibition of the CYP3A4 enzyme. Based on these observations, the co-prescription of OATP1B1 inhibitors with statins should be closely monitored in practice. However, it should be noticed that OATP1B1 inhibitors are not so numerous, including rifampin, cyclosporine, some HIV-antiprotease inhibitors, and macrolides [15] . Within OATP1B1 inhibitors, rifampicin can be considered apart because it is an inhibitor of OATP1B1 but also an inducer of CYP3A4. Hence, a single dose of rifampin induces immediately an inhibition of OATP1B1 resulting in an increase in plasma levels of statins for which OATP1B1 plays a significant role in their intake in the hepatocytes. However, this effect can be offset after a few days of co-administration by the rifampicin induction of CYP3A4 leading to a decrease in statin levels. As shown for atorvastatin, that is a lipophilic statin highly metabolized by CYP3A4, after a few days of co-administration with rifampicin, the induction of CYP3A4 prevails resulting in a decrease in atorvastatin levels [18] .
Such differences in the DDI pattern of statins may have consequences in the choice of a statin to be prescribed in patients, especially for polymedicated patients. Such differences should also be considered by the pharmacology and therapeutics committee of our institutions for the choice the statin(s) to be integrated in the medication formulary. Moreover, if a substitution has to be made in the drug treatment of patient during his/her hospital stay, as a result on a non-availability of the statin prescribed within the institution, the health professionals in charge of the medical reconciliation should pay attention to the statin substitution in order to avoid generation of DDIs.
Given the occurrence of OATP1B1-based DDIs at the highest level of severity, clinicians should be informed on the relevance of transporter-based DDIs. However, transporter-based DDIs can involve influx transporters [19] and also efflux transporters such as P-gp [20] at the hepatocyte or at the intestinal level (Fig. 4) . Transporter-based DDIs can also occur at the kidney level while many of these interactions have limited clinical consequences [21] .
Dissimilarities between DDBS
Given the differences reported in the literature in the detection of DDIs between DDBs [22] [23] [24] [25] [26] , we made a comparison of Theriaque with Micromedex as the most referenced database internationally to check for potential dissimilarities with statins.
If we consider DDIs that are contraindicated (level 1 in our study), we showed that DDI prevalence was 0.20 and 0.16% for Theriaque and Micromedex, respectively (Table 2) .On the whole, the difference was rather small. However, differences were noticed at the individual statin level. Indeed, using Theriaque contraindications fluctuated from 0.04% for pravastatin to 1.0% for rosuvastatin (Fig. 3) . However, using Micromedex, contraindications were noticed with simvastatin (1.2%) and at a lesser extent with atorvastatin (0.04%). Such difference between DDBs for level 1 severity DDIs is questioning. According to Micromedex, the drug interaction between rosuvastatin and cyclosporin is not considered as contraindicated as it is by Theriaque that is based on the national thesaurus. Conversely, Theriaque did not mention simvastatincyclosporin as a contraindication in the version we used in our study (version: 2016-08-12) . However, Theriaque identified simvastatine-cyclosporin as a contraindication after the end of our study in September 2016 and mentioned it in a supplementary material [10] . It can be quite surprising that a contraindication was not mentioned by a drug agency in the national thesaurus for such widely prescribed drugs.
Such DDI between cyclosporin and simvastatin is of paramount importance given the fact that transplant patients are frequently treated for hypercholesterolemia induced by cyclosporin, and with the fact that this interaction is very significant with a 4.1-fold increase in statin exposure potentially exposing frail patients to rhabdomyolysis [27, 28] . Indeed, physicians should be aware of such differences between DDBs especially for level 1 DDI (i.e., contraindication).
On level of severity 2 (i.e., should be avoided), DDI prevalence was 1.3 and 6.2% for Theriaque and Micromedex, respectively ( Table 2) . Prevalence of DDIs with the statins was generally higher with Micromedex compared to Theriaque, especially for the CYP3A4 metabolized statins (Fig. 3) . The most frequent DDIs on the level of severity 2 (Fig. 2b, see supplementary materials) for Micromedex (atorvastatin-diltiazem, atorvastatin-digoxine, atorvastatinedomperidone) were not listed with the same level of severity or not listed at allin Theriaque.
As a whole, the ranking of DDIs within a therapeutic class can vary according to DDI screening programs, thus impeding the comparability between studies. Such dissimilarities between DDBs have been observed in other publications mostly between US DDBs [22] [23] [24] [25] [26] . Such dissimilarities need to be quantified in order to give a global view of the extent of the differences. In our comparison, the value of Jaccard and Kendall tau coefficients (0.4 and 0.5, respectively) indicated that the dissimilarity between Theriaque and Micromedex was quite substantial either as for a global comparison than for the severity agreement. Indeed, only 50% of DDIs in Theriaque and Micromedex DDBs shared the same level of severity.
Reasons for such dissimilarities have been studied through the work of Scheife RT and al [29] . Indeed, this study pointed out the lack of standardization in inclusion DDI procedure assessment and in severity level DDI procedure assessment. According to this consensus, DDI documentation should be justified by two arguments: sufficient evidence on the existence of DDI and DDI clinical relevance. Dissimilarities observed in statin DDIs between DDBs might be explained by the variation in the assessment of these two criteria among DDBs. Moreover, there are also heterogeneity and lack of reliable sources to establish evidence to support DDI and clinical relevance [29] [30] [31] that might also be the source of dissimilarities. Observational studies that investigate clinical relevance of DDIs based on real word data from clinical data warehouse are particularly of interest to precise clinical relevance of DDIs in terms of adverse drug reaction and predictive factors compared to clinical trials.
Limitations
Several limitations of the present study should be mentioned. The first is that we did not achieve a comparison of DDI profiles before and after hospitalization. Indeed, hospitalized patients might be more exposed to DDIs compared to patients in ambulatory care as a result of potential specific treatments administered to patients.
The second limitation resides in the fact that we studied potential DDIs since the clinical consequences of these DDIs were not investigated. Moreover, we did not consider the dosing regimen of the statins in our analysis. This could be of interest given that limiting the dose of a statin and monitoring of creatine kinase may be an option to limit the consequences of a DDI.
The third limitation resides in the fact that we did not make an automatic qualitative analysis of the mechanisms of DDIs throughout the overall database. Indeed, this automatization would have required drug knowledge databases with information on mechanism of DDIs as structured information and not only in text form (unstructured data).
Another limitation arises from the fact that this study is monocentric and has been performed in patients hospitalized in a university hospital. This might represent a potential bias since patients hospitalized in a university hospital have usually more severe clinical conditions. Thus, patients either in ambulatory setting or hospitalized in other settings could have differences in nature or prevalence of DDIs.
Conclusion and perspectives
This study showed that the DDI profiles of the statins were different with a high prevalence of CYP3A4-based interactions for lipophilic statins. However, analyzing the 3 most frequent DDIs, the more significant DDIs (level 1: contraindication) were reported for transporter-based DDI involving OATP1B1 influx transporter. While least common, transporter-based DDIs should deserve more attention by health professionals. Such differences in DDI profile of statins are to be considered for the optimal choice of statin to be referenced by the P & T committee of our institutions. The current study also pointed out significant dissimilarities between DDBs in the detection of potential DDIs of statins.
Compliance with ethical standards The ethics comitee of our institution approved the study with a waiver of patient consent authorization (number 17.60). Since the design of the study is retrospective no formal consent is required.
